SpeechVive Funding: How Much Did They Raise & Key Investors

How Much Did SpeechVive Raise?
Funding & Key Investors

SpeechVive has successfully secured a total of $727K in capital to advance its mission of transforming communication for individuals living with Parkinson's disease. This latest infusion of $27K represents a strategic move to bolster the company's market presence and operational capacity. By securing this substantial expansion capital, the firm is well-positioned to scale its innovative wearable technology, which addresses the critical need for immediate improvements in speech volume and clarity for patients suffering from neurodegenerative conditions.

The company's growth trajectory, marked by its initial Series A round in 2014 and subsequent debt financing in 2021, underscores a consistent commitment to long-term sustainability and clinical efficacy. As SpeechVive continues to navigate the complex landscape of medical device commercialization, this financial backing serves as a testament to the viability of its non-invasive, therapy-alternative solutions in the broader healthcare ecosystem.

What is SpeechVive?

SpeechVive

Manufacturing

Medical Devices & Equipment

SpeechVive operates at the intersection of medical technology and patient-centric care, providing a specialized wearable device engineered to mitigate the speech-related symptoms of Parkinson's disease. Unlike traditional, time-intensive speech therapy, the SpeechVive device offers immediate, tangible results, allowing users to regain vocal clarity and volume with minimal friction. The company has achieved significant milestones in accessibility, securing approval from Medicare and various private insurance providers. This regulatory and reimbursement success positions SpeechVive as a disruptive force in the assistive technology market, offering clinicians a highly effective, scalable alternative to conventional therapeutic interventions. By focusing on immediate quality-of-life improvements, the firm has carved out a distinct niche in the neuro-rehabilitation sector.

How much funding has SpeechVive raised?

SpeechVive has raised a total of $727K across 2 funding rounds:

2014

Series A

$700K

2021

Debt

$27K

Series A (2014): $700K with participation from Ambassador Enterprises, LLC

Debt (2021): $27K led by PPP

Key Investors in SpeechVive

Ambassador Enterprises, LLC

A legacy-minded private equity firm that invests for eternal, cultural, and financial returns, focusing on organizations that create lasting positive impact.

PPP

Public-Private Partnership

What's next for SpeechVive?

With the recent influx of capital, SpeechVive is poised to accelerate its commercial outreach and deepen its penetration within the clinical market. The strategic focus will likely shift toward expanding the reach of its wearable technology to a broader patient demographic, leveraging its existing insurance coverage to lower barriers to entry. Furthermore, the company is expected to invest in ongoing clinical validation and potential product iterations to maintain its competitive edge. As the healthcare industry increasingly prioritizes cost-effective, patient-accessible solutions, SpeechVive is strategically aligned to capitalize on the growing demand for digital health tools that deliver rapid, measurable outcomes for chronic condition management.

See full SpeechVive company page

See More Financial Insights